These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10467820)

  • 41. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA Expands List of "Do Not Compound" Drug Products.
    Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services
    J Pain Palliat Care Pharmacother; 2017 Mar; 31(1):76-78. PubMed ID: 28287350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Herbal and nutritional supplement use in the elderly.
    Stupay S; Sivertsen L
    Nurse Pract; 2000 Sep; 25(9):56-8, 61-2, 64 passim. PubMed ID: 11016043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation.
    Cohen MH
    Dermatol Ther; 2003; 16(2):77-84. PubMed ID: 12919107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacy compounding primer for physicians: prescriber beware.
    Sellers S; Utian WH
    Drugs; 2012 Nov; 72(16):2043-50. PubMed ID: 23039281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Litigating the legality of compounding: the medical center pharmacy case.
    Gibbs JN
    Int J Pharm Compd; 2008; 12(3):238-41. PubMed ID: 23969713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34751-958. PubMed ID: 17674484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmaceutical and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-97. PubMed ID: 27116797
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
    Frankos VH; Street DA; O'Neill RK
    Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the Amount of Compounded Chemotherapy Drugs: A Comparison Between Nine Compounding Pharmacies.
    Bajorek SR; Hazzah TN; Chretin JD; Mills TN; McKee TS; Frank JR; Benvin-Guzzo JL; Clifton KA; Bergman PJ
    Vet Comp Oncol; 2024 Aug; ():. PubMed ID: 39164199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA.
    Cabaleiro J
    Int J Pharm Compd; 2021; 25(5):358-362. PubMed ID: 34623960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Interim final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34959-69. PubMed ID: 17674485
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 57. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs).
    Pawar RS; Grundel E
    Drug Test Anal; 2017 Mar; 9(3):500-517. PubMed ID: 27259162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A summarized discussion of current good manufacturing practice regulations.
    Allen LV
    Int J Pharm Compd; 2013; 17(3):210-9. PubMed ID: 24046937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulatory and ethical issues with dietary supplements.
    Harris IM
    Pharmacotherapy; 2000 Nov; 20(11):1295-302. PubMed ID: 11079277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.